Navigation Links
Compounds outsmart solid tumors' malfunctioning machinery
Date:7/17/2013

some under certain conditions."

The new strategy was serendipitously found during experiments with rapamycin, a drug that in a highly publicized study by the UT Health Science Center's Barshop Institute for Longevity and Aging Studies was found to extend life span in mice.

Potential

The Molecular Pharmacology report and follow-up studies describe the unexpected and highly desired effects that rapamycin and similar compounds elicit on the proteasome. Based on these studies, it would be possible to design a new line of proteasome regulators with anti-cancer properties, Drs. Osmulski and Gaczynska said. This work is in progress in their laboratory. Drs. Osmulski and Gaczynska are affiliated with the Barshop Institute and with the Cancer Therapy & Research Center at The University of Texas Health Science Center San Antonio.


'/>"/>

Contact: Will Sansom
sansom@uthscsa.edu
210-567-2579
University of Texas Health Science Center at San Antonio
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
2. Compounds activate key cancer enzyme to interfere with tumor formation
3. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
4. Dirty Drugs and We Know It: Attorneys at Console & Hollawell Comment on ISMP Survey Relating to Contaminated Drug Compounds and the Risks to Consumers
5. Advance in re-engineering photosynthesis to make drugs, compounds or ingredients
6. NIH-supported researchers identify new class of malaria compounds
7. Ginger compounds may be effective in treating asthma symptoms
8. Many solid tumors carry genetic changes targeted by existing compounds
9. Some Whooping Cough Strains Now Outsmarting Vaccine
10. AvePoint Outsmarts the Chaos with Interactive Meetings App for Microsoft SharePoint 2013
11. OHSU research highlights promising strategy to help vaccines outsmart HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Daily Gossip reveals in its Leaky Gut Cure ... and functional medicine practitioner, who spent years looking for a ... suffered from leaky gut, too, so this is what determined ... treatment. , Karen Brimeyer decided to share her story, ... the world. The author of the Leaky Gut Cure program ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... protecting the rights of victims injured by defective drugs ... has been filed by plaintiffs in Canada who allege ... of cardiovascular events with the low testosterone injection ... on July 22, 2014 in the Ontario Superior Court ...
(Date:7/29/2014)... Daily Gossip reveals in its review that ... that will permanently eliminate all the symptoms associated to this ... will banish symptoms such as mild hearing loss, as well ... patients will be gone forever. , The method will lead ... of this program says that at the end of the ...
(Date:7/29/2014)... 2014 (HealthDay News) -- Want young children to embrace ... that,s healthy is good for them. Doing so will ... new study suggests. "Parents and caregivers who are ... better off simply serving the food without saying anything ... food actually is," said study authors Michal Maimaran, of ...
(Date:7/29/2014)... Randy Dotinga HealthDay Reporter ... When most children take on a task, various brain ... neuro-boosting activity in kids with autism, according to a ... symptoms of autism displayed even less of this "brain ... flexibility often causes difficulty when children with autism are ...
Breaking Medicine News(10 mins):Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3
... from McGill University and the University of British Columbia ... expressions. McGill Psychology Prof. Jeffrey Mogil, UBC ... discovered that when subjected to moderate pain stimuli, mice ... humans do. Their study, published online May 9 in ...
... support program might be an appropriate Mother,s Day gift ... is a smoker, you might consider giving her a Mother,s ... live a longer, healthier life, suggests the American Lung Association. ... available 24 hours a day and offers users tools and ...
... ... concentrates and additive masterbatches for the plastics industry, announced plans today to open a ... PCC,s growing customer demand from the food packaging, medical device and supply, and pharmaceutical ... (PRWEB) ...
... KEL Attorneys is looking for ... , ... -- Kaufman, Englett & Lynd LLC is actively searching for individuals and businesses affected by ... a law suit on their behalf., , ,KEL Attorneys is looking for those businesses and individuals ...
... of heart disease doubled for nurses with high work pressures, ... high-pressure job can boost the risk of heart disease among ... studies have mainly looked at high-pressure jobs and men, but ... part in the Danish Nurse Cohort Study. The women were ...
... ... to its Board of Directors on April 26, 2010, Nalini N. Jairath, PhD, RN, ... four new members bring an impressive amount of experience and expertise to help support the ... ...
Cached Medicine News:Health News:McGill-UBC project creates mouse grimace scale to help identify pain in humans and animals 2Health News:Plastics Color Corporation Expands Into California 2Health News:Plastics Color Corporation Expands Into California 3Health News:KEL Attorneys is Assisting Victims of the Deepwater Horizon Oil Spill by Filling Legal Claims on Their Behalf 2Health News:Providence Hospital Appoints Four New Members to its Board of Directors 2Health News:Providence Hospital Appoints Four New Members to its Board of Directors 3
(Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
(Date:7/29/2014)... Regado Biosciences, Inc. (Nasdaq: RGDO ... clinical development of Revolixys™ Kit (previously known as REG1), ... that it will hold a conference call and live ... a.m. EDT to discuss its second quarter 2014 financial ... investors may access the conference call by dialing (877) ...
(Date:7/29/2014)... PAUL, Minn. , July 29, 2014  EnteroMedics ... medical devices using neuroblocking technology to treat obesity, metabolic ... will host a conference call on Thursday, August 7, ... results for the second quarter ended June 30, 2014 ... Call Details The second quarter conference call ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... - New data from an,investigational study released ... Scientific Sessions showed that initial,combination therapy with ... markers of beta cell,function in patients with ... determines the ability of the body to ...
... RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed ... and approval of drugs for the treatment ... noted the publication of,promising results of research ... insulin-like growth factor binding protein-3,(IGFBP-3) in the ...
Cached Medicine Technology:An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants 2Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants 3
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... quadripolar pacing wire design offers ... sensing in the atrium and ... wires in one lead design. ... and ventricle are color-coded for ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: